Last reviewed · How we verify
Rimso-50 (DIMETHYL SULFOXIDE)
Rimso-50, also known as dimethyl sulfoxide, is a small molecule drug originally developed by Mylan Institutional and currently owned by the same company. It was FDA-approved in 1978 for the improvement of symptoms in patients with interstitial cystitis and ulcerative cystitis. As an off-patent medication, Rimso-50 is available as a generic product. The commercial status of Rimso-50 is generic, with only one generic manufacturer available. Key safety considerations include the need for careful administration and potential side effects.
At a glance
| Generic name | DIMETHYL SULFOXIDE |
|---|---|
| Sponsor | Mylan Institutional |
| Drug class | dimethyl sulfoxide |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Improvement of symptoms in patients with interstitial cystitis
- Ulcerative cystitis
Common side effects
- chemical cystitis
- discomfort
- odor on the breath and skin
- garlic-like taste
Key clinical trials
- Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (PHASE2)
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread (PHASE2)
- Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (PHASE2)
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma (PHASE2)
- Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment (PHASE1,PHASE2)
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) (PHASE2)
- Effect of Local Use of Vitamin D on the Rate of Canine Distillization: a Split Mouth Randomized Control Trial (PHASE1)
- Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rimso-50 CI brief — competitive landscape report
- Rimso-50 updates RSS · CI watch RSS
- Mylan Institutional portfolio CI